A Phase 1, Randomized, Single Dose, Placebo And Active Controlled, 3-Way Crossover Study To Evaluate The Effect Of A Single Oral Dose Of Lersivirine (UK-453,061) On Qt Intervals In Healthy Subjects.

Trial Profile

A Phase 1, Randomized, Single Dose, Placebo And Active Controlled, 3-Way Crossover Study To Evaluate The Effect Of A Single Oral Dose Of Lersivirine (UK-453,061) On Qt Intervals In Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2012

At a glance

  • Drugs Lersivirine; Moxifloxacin
  • Indications Bacterial infections; HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Feb 2012 Results published in Antimicrobial Agents and Chemotherapy.
    • 03 Sep 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 03 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top